Doravirine/lamivudine/tenofovir

Doravirine/lamivudine/tenofovir (brand name Delstrigo) is a fixed-dose combination drug for the treatment of HIV/AIDS.[1][2] It contains doravirine, lamivudine, and tenofovir disoproxil.[3][2] In the United States, in August 2018, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection.[3][4]

Doravirine/lamivudine/tenofovir
Combination of
DoravirineNon-nucleoside reverse transcriptase inhibitor
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleotide reverse transcriptase inhibitor
Clinical data
Trade namesDelstrigo
Other namesMK-1439A
AHFS/Drugs.comMonograph
MedlinePlusa618049
License data
ATC code
Legal status
Legal status
Identifiers
KEGG

References
  1. "Delstrigo- doravirine, lamivudine, and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 10 October 2019. Retrieved 31 July 2020.
  2. Canadian Agency for Drugs and Technologies in Health (June 2019). "Common Drug Review New Combination Product: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination (Delstrigo)". CADTH Common Drug Reviews. Ottawa (ON). PMID 31393687.
  3. "FDA Approves Merck's DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients" (Press release). Merck & Co. 30 August 2018.
  4. "Delstrigo approval letter" (PDF). Food and Drug Administration (FDA). 30 August 2018. Retrieved 10 September 2019.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.